Latest & greatest articles for valsartan

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on valsartan or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on valsartan and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for valsartan

1. Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients

Sacubitril + valsartan (Entresto) in chronic heart failure. Favourable results in highly selected patients Prescrire IN ENGLISH - Spotlight ''Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients'', 1 February 2017 {1} {1} {1} | | > > > Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients Spotlight Every month, the subjects in Prescrire’s Spotlight. 100 most recent :  |    (...) |   |   |   |   |   |   |   |  Spotlight Sacubitril + valsartan (Entresto°) in chronic heart failure. Favourable results in highly selected patients FEATURED REVIEW Replacing an ACE inhibitor or an ARB with the high-dose sacubitril + valsartan combination should be envisaged with care, and solely for heart failure patients comparable to those included in the only available trial. Most chronic heart failure patients should continue to use

2017 Prescrire

2. Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. (PubMed)

Reduced Risk of Hyperkalemia During Treatment of Heart Failure With Mineralocorticoid Receptor Antagonists by Use of Sacubitril/Valsartan Compared With Enalapril: A Secondary Analysis of the PARADIGM-HF Trial. Consensus guidelines recommend the use of mineralocorticoid receptor antagonists (MRAs) for selected patients with symptomatic heart failure and reduced ejection fraction (HFrEF) to reduce morbidity and mortality; however, the use of MRAs in combination with other inhibitors of the renin (...) -angiotensin-aldosterone system increases the risk of hyperkalemia.To determine whether the risk of hyperkalemia associated with use of MRAs for patients with HFrEF is reduced by sacubitril/valsartan in comparison with enalapril.The PARADIGM-HF (Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial randomly assigned 8399 patients with chronic HF, New York Heart Association class II to IV symptoms, and a left ventricular EF of 40

Full Text available with Trip Pro

2016 JAMA cardiology Controlled trial quality: uncertain

3. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction

Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction Sacubitril valsartan for treating Sacubitril valsartan for treating symptomatic chronic heart failure with symptomatic chronic heart failure with reduced ejection fr reduced ejection fraction action T echnology appraisal guidance Published: 27 April 2016 nice.org.uk/guidance/ta388 © NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice (...) to eliminate unlawful discrimination, to advance equality of opportunity and to reduce health inequalities. Commissioners and providers have a responsibility to promote an environmentally sustainable health and care system and should assess and reduce the environmental impact of implementing NICE recommendations wherever possible. Sacubitril valsartan for treating symptomatic chronic heart failure with reduced ejection fraction (TA388) © NICE 2018. All rights reserved. Subject to Notice of rights (https

2016 National Institute for Health and Clinical Excellence - Technology Appraisals

4. ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex)

ENTRESTO - Sacubitril/valsartan (as sacubitril valsartan sodium hydrate complex) Search Page - Drug and Health Product Register Language selection Search and menus Search Search website Search Topics menu You are here: Summary Basis of Decision - - Health Canada Expand all Summary Basis of Decision (SBD) for Contact: Summary Basis of Decision (SBD) documents provide information related to the original authorization of a product. The for is located below. Recent Activity for SBDs written

2017 Health Canada - Drug and Health Product Register

5. CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure

CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure ©Institute for Clinical and Economic Review, 2015 CardioMEMS™ HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto™, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks Final Report December 1, 2015 Completed by: Institute for Clinical and Economic Review ©Institute for Clinical (...) and associated software for monitoring increases in pulmonary artery (PA) pressure (a key indicator of worsening CHF) known as the CardioMEMS™ HF System (St. Jude Medical), and a drug, Entresto™ (Novartis AG), a combination of the angiotensin II receptor blocker (ARB) valsartan and the neprilysin (nep-ri- li-sin) inhibitor sacubitril. The objective of this report is to evaluate the accumulated evidence on these two new interventions, to understand the context around their potential use in clinical practice

2015 California Technology Assessment Forum

6. PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure

PARADIGM?HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in Heart Failure RXFILES PRELIMINARY TRIAL SUMMARY LYNETTE KOSAR JAN 7 TH , 2015 – WWW.RXFILES.CA Page 1 of 3 PARADIGM-HF: Valsartan 160mg po BID + Sacubitril (=LCZ696) versus Enalapril 10mg po BID in HF 1 Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality & morbidity in HF BOTTOM LINE ? In PARADIGM-HF, clinically stable patients with heart failure (HF) (NYHA class I 5%, class (...) : LCZ696 375±71mg (=valsartan 300±57mg/day), Enalapril 18.9±3.4mg - MEAN SBP AT 8 MONTHS: LCZ696 3.2±0.4mmHg lower (p<0.001), but the authors stated this was not the reason for benefit when it was analyzed as a time-dependent covariate STRENGTHS, LIMITATIONS, & UNCERTAINTIES STRENGTHS: ? Important clinical endpoints (e.g. cardiovascular death, HF hospitalizations) with blinded adjudication of outcomes. ? Only 20 patients lost to follow-up (0.13%). LIMITATIONS: ? No Phase II studies have been conducted

2016 RxFiles

7. Entresto (sacubitril, valsartan) - treatment of heart failure

Entresto (sacubitril, valsartan) - treatment of heart failure Entresto (sacubitril, valsartan) × Insert searchphrase to search the website Insert searchphrase to search the website > > > Entresto (sacubitril, valsartan) Conclusion Entresto is the first medicine in the class of combined angiotensin receptor neprilysin inhibitors (ARNI) containing valsartan and sacubitril. It is indicated for the treatment of heart failure as an alternative to angiotensin converting enzyme (ACE) inhibitors

2017 Danish Pharmacotherapy Reviews

8. Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). (PubMed)

Effect of sacubitril/valsartan on recurrent events in the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Recurrent hospitalizations are a major part of the disease burden in heart failure (HF), but conventional analyses consider only the first event. We compared the effect of sacubitril/valsartan vs. enalapril on recurrent events, incorporating all HF hospitalizations and cardiovascular (CV) deaths in PARADIGM (...) 2031 (63.8%) were first events (836 CV deaths). Among a total of 1195 patients with at least one HF hospitalization, 410 (34%) had at least one further HF hospitalization. Sacubitril/valsartan compared with enalapril reduced the risk of recurrent HF hospitalization using the negative binomial model [rate ratio (RR) 0.77, 95% confidence interval (CI) 0.67-0.89], the WLW method [hazard ratio (HR) 0.79, 95% CI 0.71-0.89], the LWYY method (RR 0.78, 95% CI 0.68-0.90), and the joint frailty model (HR

Full Text available with Trip Pro

2018 European Journal of Heart Failure Controlled trial quality: uncertain

9. LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips

LCZ696 (Sacubitril/ Valsartan) ENTRESTO Summary and Practical Tips November 2015 LCZ696 (Sacubitril/Valsartan), Entresto TM Summary and Practical Tips Mechanism of action: sacubitril is a neprilysin (endopeptidase) inhibitor: ?vasodilatory peptides ? ?sodium loss, ?hypertrophy/remodeling. Combination with an ARB is necessary as inhibition of neprilysin leads to activation of the renin angiotensin aldosterone system (RAAS). Indication: • Health Canada Indication 1 : heart failure with reduced (...) ejection fraction (HFrEF), NYHA class II-III, in combination with other heart failure (HF) therapies in place of an ACEI or ARB • CCS HF 2014 Guidelines 2 : mild-moderate HF, left ventricular ejection fraction (LVEF) 5.2 mmol/L • History of angioedema Dosing: • Tablet: film-coated, unscored containing both sacubitril and valsartan (dose is sum of agents) • Strengths: 50 mg (24/26mg; white), 100 mg (49/51mg; yellow), 200 mg (97/103mg; pink) o Note: different valsartan salts; Entresto TM valsartan 103mg

2016 RxFiles

10. Valsartan

Valsartan Top results for valsartan - Trip Database or use your Google+ account Find evidence fast ALL of these words: Title only Anywhere in the document ANY of these words: Title only Anywhere in the document This EXACT phrase: Title only Anywhere in the document EXCLUDING words: Title only Anywhere in the document Timeframe: to: Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4 (...) ) Loading history... Population: Intervention: Comparison: Outcome: Population: Intervention: Latest & greatest articles for valsartan The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted

2018 Trip Latest and Greatest

11. Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure (PubMed)

Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure 27668049 2016 09 26 2018 11 13 1942-2962 9 Spec Feature 2016 Mar American health & drug benefits Am Health Drug Benefits Entresto (Sacubitril/Valsartan): First-in-Class Angiotensin Receptor Neprilysin Inhibitor FDA Approved for Heart Failure. 78-82 Fala Loretta L eng Journal Article United States Am Health Drug Benefits 101479877 1942-2962 2016 9 27 6 0 2016 9 27 6 0 2016 9

Full Text available with Trip Pro

2016 American health & drug benefits

12. Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin- (PubMed)

Incidence, Predictors, and Outcomes Associated With Hypotensive Episodes Among Heart Failure Patients Receiving Sacubitril/Valsartan or Enalapril: The PARADIGM-HF Trial (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin- In PARADIGM-HF (Prospective Comparison of Angiotensin Receptor Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure), heart failure treatment with sacubitril (...) /valsartan reduced the primary composite outcome of cardiovascular death or heart failure hospitalization compared with enalapril but resulted in more symptomatic hypotension. Concern on hypotension may be limiting use of sacubitril/valsartan in appropriate patients.We characterized patients in PARADIGM-HF by whether they reported hypotension during study run-in periods (enalapril, followed by sacubitril/valsartan) and after randomization and assessed whether hypotension modified the efficacy

Full Text available with Trip Pro

2018 Circulation. Heart failure

13. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. (PubMed)

Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy. In the PARADIGM-HF trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure), the angiotensin receptor neprilysin inhibitor sacubitril/valsartan was more effective than the angiotensin-converting enzyme inhibitorenalapril in patients (...) (31%) had undergone coronary revascularization. Overall, the sacubitril/valsartan versus enalapril hazard ratio for the primary composite end point was 0.80 (95% confidence interval,0.73-0.87;P<0.001) and for cardiovascular death was0.80 (0.71-0.89;P<0.001). The effect of sacubitril/valsartan was consistent across all subgroups examined. The hazard ratio for primary end point ranged from 0.74 to 0.85 and for cardiovascular death rangedfrom 0.75 to 0.89, with no treatment-by-subgroup

Full Text available with Trip Pro

2016 Circulation. Heart failure Controlled trial quality: uncertain

14. Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. (PubMed)

Efficacy and effectiveness of valsartan/amlodipine and valsartan/amlodipine/hydrochlorothiazide in hypertension: randomized-controlled versus observational studies. The aim of this post-hoc analysis was to compare the results from randomized controlled trials (RCTs) and real-world evidence (RWE) studies of valsartan/amlodipine (Val/Aml) and valsartan/amlodipine/hydrochlorothiazide (Val/Aml/HCTZ) in patients with uncontrolled hypertension (>140/90 mmHg).Data was pooled from 15 RCTs (N = 5542

2017 Current medical research and opinion

15. Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. (PubMed)

Effects of Sacubitril/Valsartan on Physical and Social Activity Limitations in Patients With Heart Failure: A Secondary Analysis of the PARADIGM-HF Trial. Health-related quality of life (HRQL) of patients with heart failure is markedly reduced compared with that in patients with other chronic diseases, demonstrating substantial limitations in physical and social activities. In the Prospective Comparison of ARNI With an ACE-Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart (...) Failure (PARADIGM-HF) trial, sacubitril/valsartan improved overall HRQL compared with enalapril, as determined by the Kansas City Cardiomyopathy Questionnaire (KCCQ).To examine the effects of sacubitril/valsartan on physical and social activities.The PARADIGM-HF trial was a randomized, double-blind, active treatment-controlled clinical trial performed from December 8, 2009, to March 31, 2014, in 8399 patients with New York Heart Association class II to IV disease and a left ventricular ejection

Full Text available with Trip Pro

2018 JAMA cardiology Controlled trial quality: predicted high

16. Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. (PubMed)

Effect of sacubitril/valsartan versus enalapril on glycaemic control in patients with heart failure and diabetes: a post-hoc analysis from the PARADIGM-HF trial. Diabetes is an independent risk factor for heart failure progression. Sacubitril/valsartan, a combination angiotensin receptor-neprilysin inhibitor, improves morbidity and mortality in patients with heart failure with reduced ejection fraction (HFrEF), compared with the angiotensin-converting enzyme inhibitor enalapril, and improves (...) peripheral insulin sensitivity in obese hypertensive patients. We aimed to investigate the effect of sacubitril/valsartan versus enalapril on HbA1c and time to first-time initiation of insulin or oral antihyperglycaemic drugs in patients with diabetes and HFrEF.In a post-hoc analysis of the PARADIGM-HF trial, we included 3778 patients with known diabetes or an HbA1c ≥6·5% at screening out of 8399 patients with HFrEF who were randomly assigned to treatment with sacubitril/valsartan or enalapril

Full Text available with Trip Pro

2017 The lancet. Diabetes & endocrinology Controlled trial quality: uncertain

17. A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension

A systematic review and meta-analysis of telmisartan vs valsartan in the management of essential hypertension Untitled Document The CRD Databases will not be available from 08:00 BST on Friday 4th October until 08:00 BST on Monday 7th October for essential maintenance. We apologise for any inconvenience.

2010 DARE.

18. Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure ( (PubMed)

Influence of Ejection Fraction on Outcomes and Efficacy of Sacubitril/Valsartan (LCZ696) in Heart Failure with Reduced Ejection Fraction: The Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure ( The angiotensin receptor neprilysin inhibitor sacubitril/valsartan (LCZ696) reduced cardiovascular morbidity and mortality compared with enalapril in patients with heart failure (HF) and reduced ejection fraction (EF) in the Prospective (...) Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial. We evaluated the influence of EF on clinical outcomes and on the effectiveness of sacubitril/valsartan compared with enalapril.Eight thousand three hundred ninety-nine patients with New York Heart Association class II to IV HF with reduced EF [left ventricular EF (LVEF) ≤40%] were randomized to sacubitril/valsartan 97/103 mg twice daily versus enalapril 10 mg twice daily and followed

Full Text available with Trip Pro

2016 Circulation. Heart failure Controlled trial quality: predicted high

19. Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients (PubMed)

Hierarchical Modeling of Patient and Physician Determinants of Blood Pressure Outcomes in Hypertensive Patients with and without Diabetes: Pooled Analysis of Six Observational Valsartan Studies with 15,282 Evaluable Patients We pooled data from 6 valsartan-related studies including 3,658 diabetic and 11,624 nondiabetic patients to evaluate blood pressure (BP) outcomes after approximately 90 days of second- or later-line valsartan treatment. Hierarchical linear and logistic regressions were (...) included age, BP at diagnosis of hypertension, risk factors, valsartan regimen, concomitant antihypertensive treatment, and adherence; and physician-related determinants included gender, years in practice, and hypertension management. In summary, in both diabetic and nondiabetic patients, the use of valsartan-centric treatment regimens in second- or later-line antihypertensive treatment is associated with significant reductions in BP level and improvement in BP control. The determinants identified

Full Text available with Trip Pro

2017 International journal of chronic diseases

20. Insights into implementation of sacubitril/valsartan into clinical practice (PubMed)

Insights into implementation of sacubitril/valsartan into clinical practice Sacubitril/valsartan significantly reduced heart failure hospitalization and mortality in PARADIGM-HF (Prospective Comparison of Angiotensin Receptor-Neprilysin Inhibitor With an Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure). However, real-world data from its use are lacking.We retrospectively assessed all baseline and follow-up data of consecutive heart (...) failure patients with reduced ejection fraction receiving therapy with sacubitril/valsartan for Class I recommendation between December 2016 and July 2017. Baseline characteristics and dose titration of sacubitril/valsartan were compared between patients in clinical practice and in PARADIGM-HF. A total of 120 patients (81% male) were switched from angiotensin-converting enzyme inhibitor or angiotensin receptor blocker to sacubitril/valsartan. A total of 20.1% of patients received dose uptitration

Full Text available with Trip Pro

2018 ESC heart failure Controlled trial quality: uncertain